Research programme: metabolic disorders therapy/Prader-Willi syndrome - Phytopharm
Alternative Names: P64; PYM60004 seriesLatest Information Update: 26 May 2010
At a glance
- Originator Phytopharm
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prader-Willi syndrome
Most Recent Events
- 26 May 2010 Discontinued - Preclinical for Prader-Willi syndrome in USA (unspecified route)
- 06 Oct 2003 Phytopharm is evaluating active molecules for P 64
- 17 Jan 2003 Preclinical trials in Obesity in USA (unspecified route)